Jiping Sun, Aiping Yin, Wenjing Zhang, Jia Lv, Yu Liang, Huixian Li, Yan Li, Xudong Li
Clear cell renal cell carcinoma (ccRCC) is the prominent histological subtype of renal cell carcinoma (RCC) with high incidence of local recurrence and distant metastasis. It has been documented that circular ribonucleic acids (circRNAs) play crucial roles in the development of cancers; however, study on exploring the role of circRNAs in ccRCC still remains limited. In the present study, we aimed to evaluate the biological function of a novel circRNA UBAP2 (circUBAP2) in ccRCC and the underlying mechanism. Our results showed that circUBAP2 expression was significantly down-regulated in ccRCC tissues and cell lines. Overexpression of circUBAP2 significantly inhibited the proliferation, migration, and invasion of ccRCC cells. MiR-148a-3p was a target miRNA of circUBAP2 in ccRCC cells, and its expression levels in ccRCC tissues and cell lines were negatively correlated with circUBAP2 levels. Moreover, miR-148a-3p reversed the inhibitory effects of circUBAP2 on cell proliferation, migration, and invasion in ccRCC cells. Additionally, forkhead box K2 (FOXK2) was found to be a target gene of miR-148a-3p and regulated by miR-148a-3p in ccRCC cells. Furthermore, knockdown of FOXK2 reversed the inhibitory effects of miR-148a-3p inhibitor on ccRCC cells. In conclusion, these findings indicated that circUBAP2 functioned as a novel tumor suppressor in ccRCC through regulating the miR-148a-3p/FOXK2 axis. Therefore, circUBAP2 might serve as a potential therapeutic target for the treatment of ccRCC.
APMIS. 2018 Sep;126(9):722-731
[PMID:
30160020]
Adv Exp Med Biol. 2018;1087:245-257
[PMID:
30259372]
Hum Pathol. 2017 Sep;67:18-29
[PMID:
28411178]
Cancer Lett. 2017 May 28;394:1-12
[PMID:
28089832]
Zhongguo Fei Ai Za Zhi. 2017 Dec 20;20(12):800-807
[PMID:
29277177]
Adv Exp Med Biol. 2018;1087:171-187
[PMID:
30259366]
Curr Opin Genet Dev. 2018 Feb;48:121-127
[PMID:
29245064]
Oncotarget. 2017 Jul 10;8(42):73271-73281
[PMID:
29069868]
Cell Cycle. 2018;17(23):2644-2654
[PMID:
30488762]
Oncol Lett. 2019 May;17(5):4437-4442
[PMID:
30988813]
Am J Physiol Cell Physiol. 2019 Aug 1;317(2):C177-C188
[PMID:
30969781]
Ann Surg Oncol. 2014 Mar;21(3):1046-54
[PMID:
24242678]
J Neurooncol. 2018 May;137(3):493-502
[PMID:
29335913]
J Cell Physiol. 2015 May;230(5):1013-23
[PMID:
25216324]
Int J Cancer. 2018 Jun 15;142(12):2543-2557
[PMID:
29368368]
Oncotarget. 2017 Jun 27;8(37):61687-61697
[PMID:
28977896]
Mol Med Rep. 2018 Nov;18(5):4356-4364
[PMID:
30221666]
Adv Exp Med Biol. 2018;1087:239-243
[PMID:
30259371]
Adv Exp Med Biol. 2019;1134:177-191
[PMID:
30919338]
Oncol Rep. 2017 Apr;37(4):2335-2347
[PMID:
28260088]
Biochem Soc Trans. 2016 Aug 15;44(4):1073-8
[PMID:
27528754]
Biochem Biophys Res Commun. 2018 Nov 10;505(4):996-1002
[PMID:
30314706]
Nat Rev Dis Primers. 2017 Mar 09;3:17009
[PMID:
28276433]
Hepatogastroenterology. 2009 May-Jun;56(91-92):667-71
[PMID:
19621677]
Nat Rev Drug Discov. 2017 Mar;16(3):167-179
[PMID:
27444227]
Kidney Int. 2018 Sep;94(3):471-483
[PMID:
29661544]
Acta Pharmacol Sin. 2018 Jul;39(7):1100-1109
[PMID:
29565037]
Am J Cancer Res. 2015 Jan 15;5(2):472-80
[PMID:
25973291]
Expert Rev Anticancer Ther. 2008 Jan;8(1):63-73
[PMID:
18095884]
Front Mol Biosci. 2017 Jun 06;4:38
[PMID:
28634583]